Vitamin D in der komplementären Onkologie

• Literatur

• 1 Abbas S, Linseisen J, Slanger T et al Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer – results of a large case-control study. Carcinogenesis 2008; 29(1): 93-93
• 2 Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥=33 ng/ml. Osteoporos Int 2012; [Epub ahead of print]
• 3 Churilla TM, Brereton HD, Klem M, Peters CA. Vitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease: a community oncology experience. Nutr Cancer 2012; 64 (4): 521-521
• 4 Drake MT, Maurer MJ, Link BK et al Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28(27): 4191-4191
• 5 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29(4) e81–e8
• 6 Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009; 19(7): 468-468
• 7 Goodwin PJ, Ennis M, Pritchard KI et al Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27(23): 3757-3757
• 8 Gorham ED, Garland CF, Garland FC et al Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32(3): 210-210
• 9 Gröber U, Holick MF, Kisters K. Vitamin D and drugs. Med Monatsschr Pharm 2011; 34(10): 377-377
• 10 Gröber U, Holick MF. Vitamin D: Die Heilkraft des Sonnenvitamins. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2013
• 11 Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermato-Endocrinol 2012; 4(2): 158-158
• 12 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-266
• 13 Holick MF. Vitamin D: Physiology, Molecular Biology, and Clinical Applications. 2^nd ed New York: Humana Press/Springer Science; 2010
• 14 Khan QJ, Reddy PS, Kimler BF et al Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119(1): 111-118
• 15 Krishnan AV, Swami S, Feldman D. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 2012; 77(11): 1107-1107
• 16 Prieto-Alhambra D et al Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125(3): 869-869
• 17 Prieto-Alhambra D, Servitja S, Javaid MK et al Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. Breast Cancer Res Treat 2012; 133(3): 1159-1159
• 18 Santini D et al Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21(1): 185-185
• 19 Zittermann A. The estimated benefits of vitamin D for Germany. Mol Nutr Food Res 2010; 54(8): 1164-1164
• 20 Zittermann A, von Helden R. Grant WB et al An estimate of the survival benefit of improving vitamin D status in the adult German population. Dermato-Endocrinology 2009; 1(6): 300-300